News
One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...
Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...
Broadcom, Philip Morris, and Novo Nordisk face contrasting outlooks as AI growth, smoke-free expansion, and obesity drug ...
Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...
6h
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...
Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...
Zacks Investment Research on MSN9h
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
1d
ATTENTION NYSE: NVO INVESTORS: Contact Berger Montague About a Novo Nordisk A/S Class Action Lawsuit
Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback